Testagen

Testagen is a synthetic tetrapeptide Lys-Glu-Asp-Gly (KEDG), developed as a testicular/gonadal tissue bioregulator by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology. It is derived from bovine testicular tissue and proposed to modulate testosterone biosynthesis and Leydig cell function through epigenetic mechanisms.

**Important nomenclature note:** Testagen (KEDG) should not be confused with Vesugen (KED). Vesugen is the Lys-Glu-Asp **tripeptide** (3 amino acids). Testagen is the Lys-Glu-Asp-**Gly tetrapeptide** (4 amino acids, with Gly added at the C-terminus). These are distinct compounds despite overlapping names in some vendor catalogs.

**Evidence status:** Testagen has no confirmed peer-reviewed publications with a PubMed-indexed PMID for standalone characterization. It is referenced within Khavinson's comprehensive bioregulator review articles but lacks the primary animal study data that other Khavinson tetrapeptides (Pancragen, Vesugen, Livagen) have published. It represents the thinnest evidence base in the vendor-sold Khavinson peptide series.

Testagen is proposed, by analogy with other Khavinson-class bioregulators, to act through peptide-DNA interaction in Leydig cells of the testis: the KEDG tetrapeptide is hypothesized to penetrate cell and nuclear membranes, interact with steroidogenesis gene regulatory sequences (StAR, CYP11A1, HSD3B), and modulate testosterone biosynthetic capacity that declines with aging.

This mechanism is theoretical extrapolation from the Khavinson bioregulator class framework and has not been validated by published data for Testagen specifically. No receptor binding assay, gene expression study, or functional steroidogenesis measurement has been published with confirmed PMID for KEDG.